Earnings call: TELA Bio reports robust Q4 growth, optimistic 2024 outlook By Investing.com

TELA Bio, Inc. (NASDAQ:) has announced its financial results for the fourth quarter and the full year of 2023, demonstrating significant revenue growth and a positive forecast for 2024. The company reported a 13% increase in fourth-quarter revenue to $17 million compared to the previous quarter, and a 46% increase compared to the same period in 2022.

TELA Bio’s sales of OviTex and OviTex PRS products surpassed 5000 units in the fourth quarter, with PRS representing about one-third of the total revenue. With a strong cash position and strategic product and market initiatives, TELA Bio is setting an optimistic revenue target for 2024 and anticipates reduced operating and net losses.

Key Takeaways

• Fourth-quarter revenue reached $17 million, a 13% increase from the previous quarter and a 46% increase year-over-year.
• Over 5000 OviTex and OviTex PRS products were sold, with PRS comprising roughly one-third of the revenue.
• TELA Bio launched two LIQUIFIX products in the U.S. for hernia repair.
• The company expects 2024 revenues to be between $74 million and $76 million, indicating 27% to 30% growth.
• Operating and net losses are projected to be lower in 2024, with sufficient cash to fund operations to profitability.
• TELA Bio sold NIVIS distribution rights and inventory for $8 million to $12 million.
• The company is focusing on market education for OviTex in minimally invasive robotic cases and expanding GPO contracts and LIQUIFIX indications.

Company Outlook

• TELA Bio anticipates 2024 revenues to range from $74 million to $76 million, a significant growth of 27% to 30% over 2023.
• The company plans to incentivize sales reps to sell a balanced mix of hernia and PRS products.
• TELA Bio aims to increase the number of accounts using both product lines from 50% to 80-90%.

Bearish Highlights

• TELA Bio expects to continue experiencing operating and net losses in 2024, though they predict these will be lower than in 2023.

Bullish Highlights

• The U.S. commercial launch of LIQUIFIX products is expected to contribute to revenue growth.
• The divestiture of NIVIS is set to provide an additional financial cushion of $8 million to $12 million.
• TELA Bio’s cash and cash equivalents of $46.7 million are believed to be sufficient to reach profitability.

Misses

• NIVIS, which was less significant in revenue generation, accounted for less than $300,000 of TELA’s total revenue in 2023.

Q&A Highlights

• CEO Antony Koblish confirmed that the average selling price for TELA Bio’s portfolio will remain at or improve upon current levels.
• The company is actively working to secure more GPO contracts, with expectations to implement new contracts by the end of this year or early next year.
• New sales representatives are being trained to reach breakeven within six months, in line with past productivity levels.

In conclusion, TELA Bio’s strong performance in the fourth quarter of 2023 and its strategic initiatives signal a robust outlook for 2024. With the launch of new products, a focus on market education, and expansion into new contracts, the company is well-positioned for continued growth and a path toward profitability.

InvestingPro Insights

TELA Bio, Inc. (TELA) has demonstrated robust revenue growth in the fourth quarter of 2023, yet it’s essential to consider a comprehensive financial perspective. Based on the latest InvestingPro data, TELA holds a market capitalization of $131.02 million, which reflects the market’s valuation of the company. Despite the positive sales figures, the company’s P/E ratio stands at -2.71, indicating that it is not currently profitable. Moreover, the P/E ratio has slightly worsened over the last twelve months as of Q3 2023 to -2.99, underscoring the challenges TELA faces in achieving profitability.

Revenue growth remains a bright spot, with a significant increase of 39.05% over the last twelve months as of Q3 2023. This aligns with the company’s reported sales success of its OviTex and OviTex PRS products. However, an InvestingPro Tip highlights that analysts have revised their earnings expectations downwards for the upcoming period, which could signal caution for investors expecting continuous growth.

Another InvestingPro Tip points out that TELA is quickly burning through cash, a critical consideration given the company’s ambitious growth and market expansion plans. This is particularly relevant as TELA does not pay a dividend to shareholders, emphasizing the need for the company to manage its cash flow effectively to sustain operations and growth initiatives.

For investors looking for more in-depth analysis and additional insights, there are 7 more InvestingPro Tips available for TELA Bio, Inc. These tips can provide a more nuanced understanding of the company’s financial health and future prospects. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking valuable information that could help in making more informed investment decisions.

Full transcript – Tela Bio Inc (TELA) Q4 2023:

Operator: Good afternoon ladies and gentlemen and welcome to the TELA Bio Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder this conference call is being recorded. I would now like to turn the conference over to Louisa Smith from the Gilmartin Group.

Louisa Smith: Thank you, Michelle, and good afternoon everyone. Earlier today, TELA Bio released financial results for the fourth quarter and full year 2023. A copy of the press release is available on the company’s website. Joining me on today’s call are Tony Koblish, President and Chief Executive Officer; and Roberto Cuca, Chief Operating Officer and Chief Financial Officer. Before we begin, I’d like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company’s past and future filings with the SEC including, without limitation, the company’s Annual Report on Form 10-K and quarterly reports on Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development and pipeline opportunities, products potential, the impact of various macroeconomic conditions, including the lingering effects of the COVID-19 pandemic, recessionary concerns, banking instability and inflationary pressures, the regulatory environment, sales and marketing strategies, capital resources or operating performance. With that, I’ll now turn the call over to Tony.

Antony Koblish: Thank you, Louisa. Good afternoon everyone and thanks for joining us today for TELA’s fourth quarter and full year 2023 earnings call. Today, I’d like to cover two main topics; how we did in the just completed quarter and year and how we laid the foundation for even greater performance in 2024. Our fourth quarter was very strong and I’m delighted to report that we have never been better positioned for success in our history as you will hear today. As a result of our outstanding Q4, we entered 2024 with considerable momentum, which is reflected in our guidance. Fourth quarter revenue was $17 million, up 13% sequentially from the third quarter and 46% over the fourth quarter of 2022. I’ll note that this is the 12th consecutive quarter we’ve had at least 35% year-over-year top line growth with an average growth rate over those twelve quarters of 49%. In the fourth quarter, we sold more than 5000 pieces of OviTex and OviTex PRS combined, and PRS now accounts for approximately one third of our total revenue. PRS revenues grew 75% year-over-year year versus 34% for the hernia products and we expect this pattern to continue given that PRS is the more recently launched product line. When we last spoke to you in November, we described several initiatives we had launched to increase sales productivity after we experienced some disruption in the third quarter. Specifically, we rolled out updated continuous training programs for our new reps, more intensive training on OviTex’s PRS for all reps, and incentive programs targeted at those reps who appeared to be falling short of quota as well as those who are on track to surpass it. We believe these programs are part of what helped us achieve record revenues in the fourth quarter, so we are going to continue the training and over quota incentive programs while adding a new incentive target targeting balanced selling across our product lines. As we’ve described to you in the past, accounts that buy both our hernia and PRS products tend to be more than twice as valuable as accounts that only buy one or the other product. That is, one plus one doesn’t equal two, it comes to something more like three or four. Leveraging the new PRS training we’ve launched, we are going to start incentivizing reps to sell both products, providing greater compensation to those who succeed in doing this. We expect this initiative to be a real contributor to revenue growth in 2024 and beyond. One big difference in 2024 from last year is that we are beginning the year with essentially the full complement of reps we expect to end the year with. Our goal last year was to grow to a field sales force of 75 to 80 reps, and we achieved that and beyond expanding from 61 reps we exited 2022 with to 86 reps and eight assistant reps at the end of 23. As of the end of February, we had 86 reps and six assistant reps. We plan to remain at these levels throughout 2024, perhaps adding a few opportunistically, with some of the assistants likely converting to full reps over the course of the year. What this means is that the variability in our rep count is not likely to negatively affect sales in 2024, and from a productivity perspective, more than 75% of our reps have been with us for six months or more, which remains the average for a rep to reach breakeven or the point where they are covering their own variable costs. We expect we will continue to see turnover in 2024, although at lower rates than in prior years and with little expected negative impact. Our focus for the year then, is not on recruiting but on training and improving the productivity of the reps we have on board. Playbook 90 remains the cornerstone of today’s efforts, supplemented with the additional, more intensive training described earlier. I am actually speaking to you today from our national sales meeting, where we have rolled out two significant new product offerings for our sales force to promote. Earlier today, we announced the full formal U.S. commercial launch of two LIQUIFIX products we have licensed exclusively from our partner, Advanced Medical Systems. These are the LIQUIFIX FIX8 Laparoscopic and LIQUIFIX Precision, open hernia mesh fixation devices. The first is indicated for minimally invasive femoral and inguinal hernia repairs and for approximation of the peritoneum, while the second is indicated for open inguinal and femoral hernia repairs. Both products have been available and successful in European markets for more than three years. We’re really excited about the opportunity to bring LIQUIFIX to the U.S. because it is the only FDA approved PMA product that affixes mesh and approximates tissue with liquid anchors, reducing the use of intrusive mechanical tacks, sutures, or staples. The two LIQUIFIX products are designed to minimize the risk of mechanical tissue trauma. As we’ve often said, we want to create a portfolio that drives growth, increases awareness, expands market share for products across our entire hernia franchise, and demonstrates our commitment to improving all aspects of hernia repair. We believe LIQUIFIX will do just that by offering greater utility for surgical mesh in inguinal hernia repair by enabling mesh fixation to sensitive areas such as the triangle of doom and the triangle of pain, regions in the groin, where other penetrating or fixation methods could result in vascular or nerve injuries and cause chronic pain. We also introduced our reps to OviTex IHR, our new OviTex inguinal hernia repair product, a next generation soft tissue repair platform designed specifically for inguinal hernia repair. Just like our other OviTex devices, OviTex IHR uniquely utilizes layers of sheep rumen reinforced with just enough polymer suture for added strength. And of course, all OviTex devices are designed to leverage a patient’s natural healing response, facilitate tissue remodeling, and optimize strength. OviTex IHR will be available in three configurations, two anatomically shaped and one rectangular, all of which are specifically designed for inguinal hernia repair via robotic and laparoscopic approaches. TELA remains committed to the future of robotics and minimally invasive surgery with OviTex, and we’re taking many steps this year to advance the recognition of our products as the first choice for minimally invasive hernia repair. We expect to formally launch OviTex IHR in the U.S. in the second quarter of 2024.

NIVIS Fibrillar Collagen Pack, a:

Regenity Biosciences:

NIVIS:

NIVIS: I’ll now turn the call over to Roberto to review our financial results and 2024 outlook.

Roberto Cuca: Thanks Tony. As Tony mentioned earlier, revenue for the fourth quarter of 2023 increased 46% year-over-year to $17 million and grew 41% for the year to $58.5 million, with OviTex growing 36% and OviTex PRS growing 51% for the year. These increases were primarily due to an increase in unit sales of our products and the continued expansion of our commercial organization. Each of these resulted in increased penetration of our existing customer accounts as well as the addition of new customers and growth in international sales. Gross margin was 68% for the fourth quarter and 69% for the full year, compared to 70% and 65% for the prior year periods respectively. The slight decrease in the fourth quarter of 2023 versus the fourth quarter of 2022 was primarily due to an increase in our excess and obsolete inventory adjustments incurred during that period. For the full year the gross margin improvement was driven by improved inventory management processes and lower amortization of intangible assets. Sales and marketing expense was $17.2 million in the fourth quarter of 2023 compared to $11.6 million in the same period in 2022. This increase was mainly due to higher salary, benefit and commission costs as a result of the expansion of our commercialization organization, higher travel and consulting expenses, and additional employee related costs due to increased headcount. As Tony mentioned earlier, we hired in the fourth quarter of 2023 to achieve the steady-state sales force size we expect for 2024. The effect was to increase expense at the end of 2023, but once that normalizes over the first quarter of 2024, we expect sales and marketing expense to be relatively level for the rest of 2024. General and administrative expense was $4.1 million compared to $3.2 million in the same period in 2022. R&D expense was $2.7 million in the fourth quarters of both 2023 and 2022. Loss from operations was $12.3 million in the fourth quarter of 2023 compared to $9.4 million in the prior year period. Net loss was $12.9 million in the fourth quarter of 2023 compared to $10 million in the same period in 2022. We ended 2023 with $46.7 million in cash and cash equivalents. We ended 2023 with $46.7 million in cash and cash equivalents. This does not include any of the $8 million to $12 million consideration for the sale of NIVIS distribution rights or the value of NIVIS inventory we sold as part of the transaction, both of which occurred in the first quarter of this year. Note that in 2023, NIVIS accounted for less than $300,000 of TELA’s total revenue. Turning to the outlook for 2024, we anticipate revenues to be in the range of $74 million to $76 million, representing growth of 27% to 30% over the full year of 2023. As we have said in the past, we expect operating loss and net loss to be less in 2024 than in 2023, even excluding the contribution from the divestiture of NIVIS. Moreover, we expect operating expenses to be reasonably steady over the course of the year, notwithstanding some typical seasonality and expense. And since we expect revenue to grow sequentially, both operating loss and net loss should decline directionally over the course of the year, again even excluding the contribution from the divestiture of NIVIS. As we have said in the past, we believe that our cash and cash equivalents, even before the proceeds from the divestiture of NIVIS, are sufficient to fund us to profitability and the incremental $8 million to $12 million will only provide additional cushion to this. We have an exciting year ahead of us and I look forward to updating you over the course of it. With that, I’ll hand the call back to Tony for closing remarks.

Antony Koblish: Thanks Roberto and thank you everyone for your interest in TELA Bio. I’m proud of what our team accomplished in 2023. We made exceptional progress in expanding awareness around the OviTex and OviTex PRS portfolio and the efficacy of our mesh in optimizing clinical outcomes and soft tissue preservations. Throughout 2023, we dedicated resources to introduce more than 10,000 specialized hernia and plastic reconstructive surgeons at 72 industry and society meetings to our brand and product portfolio, and we educated more than 1500 surgeons globally through TELA Bio Lab and other educational program offerings on the safe and effective use of our products. One of TELA’s key differentiators is the compatibility of our reinforced biologic products with hernia procedures performed robotically and laparoscopically. In 2024, we plan to continue educating the market with a particular emphasis on the use of OviTex in minimally invasive robotic cases. As part of that initiative, we are excited for TELA to be part of the upcoming Intuitive Surgical (NASDAQ:) Connect meeting next month. In closing, our team is poised to deliver another strong year of financial performance and solid execution. I would like to thank all those at TELA for their part in making 2023 such a success and setting us up for continued outstanding work in 2024. With that, I’ll now ask Michelle to open the line for your questions.

Operator: Thank you. [Operator Instructions] And our first question is going to come from the line of Frank Takkinen with Lake Street Capital Markets. Your line is open. Please go ahead.

Frank Takkinen: Great. Thanks for taking the questions. Congrats on a really strong finish to the year. I was hoping to start with one on the 2024 guidance. Obviously you had a strong start or strong end of the year and typical medtech seasonality supports that. How should we be thinking about Q1? Obviously we’re a good portion of the way through that and then the ramp of revenues to achieve the guided range throughout 2024?

Roberto Cuca: Sure. Thanks for the question, Frank. So we expect that the seasonality that we’ve seen in previous years is likely to replicate in 2024. So that means that the first quarter is typically flat to slightly downish from the preceding fourth quarter, and then the quarters succeeding the first quarter grow from that, with a step up from the first to the second quarter typically being one of the larger incremental steps in the year. We’ve talked about some of the factors that drive the very strong fourth quarter and then are essentially pulling some revenue from the first quarter into the fourth quarter in the past, those are a couple of things. One is a lot of patients like to use up HSAs at the end of the year if they have copays for surgeries. We understand that some patients will schedule their surgeries around the holidays so they have family at home to look after them and then both physicians and sales reps are trying to make numbers for the end of the year. So that typically produces a bit of a push at the end of the year. So we do expect, notwithstanding the leveling off of our sales force, that sort of seasonality to persist.

Antony Koblish: I’ll just add a little bit of color Frank, additional to what Roberto said, I don’t think Q1 is going to behave much differently than the normal seasonality patterns that Roberto suggested. But by us building out the sales force to the desired size in Q4 and getting the time and tenure and maturity on them, we’re really setting up for that Q2 and beyond, which is generally a great step up for us. So that’s a little bit behind the thinking.

Frank Takkinen: Okay, that’s helpful. And then let me go just ask one more and then hop back in queue. Clearly a lot of conversation about robotic inguinal IHR I’m assuming is going after that market. A lot of volume there in the inguinal space. Maybe just kind of recap that whole topic of positioning yourself correctly and the robotic tailwind, as well as the volumes in inguinal, the opportunity there, IHR specifically, and the excitement around that area and how we should be thinking about that throughout the year and going forward.

Antony Koblish: Sure Frank. So we’ve got about four or five years of experience in the inguinal space, but it’s a little bit not optimized. But it was a very ideal period of time to learn and to make sure that we baked in our product portfolio design, technique design and pricing scheme to work. So it gave us a great test bed. We started off with templates that the surgeon could trace out the unique shapes. We developed various rolling techniques to get it down the intuitive trocars and then various techniques from there. And we had some success, but we were using the basic product portfolio that is more applicable to the ventral space, so the pricing is a little bit misaligned. So what we’ve been able to do is take all the learning from that template program and just bake it right into the product. We’ve made the product thinner, we’ve added a little bit more polymer. We’ve gone from a grid shape pattern to a triaxial pattern, which I think is ideal for deployment, maybe a little stickiness inside the body and superb for strength given that the product is a little bit thinner. We’ve been able to maintain a similar strength to other products. And finally, we’re taking all those technique learnings and we’re adjusting the price for this set of products to be super competitive in what I will call the premium segment of the inguinal market. And so, as we’ve mentioned in the script, we’ll have this product on the shelf at some point in April or Q2 and we expect to roll it out with the sales force after all this learning that’s taken place over the years. And we’re really pleased to expose our company to our sales team, to this product, at the national sales meeting today. So we’re getting great head start on the launch.

Frank Takkinen: Perfect. Good color. I’ll stop there. Congrats on the progress.

Antony Koblish: Thanks, Frank.

Operator: Thank you. And one moment, as we move on to our next question. And our next question is going to come from the line of Caitlin Cronin with Canaccord Genuity. Your line is open. Please go ahead.

Caitlin Cronin: Hi, everyone. Thanks for taking my questions and congrats on an awesome quarter. Just to start, can we touch on GPO contracts and how you were ramping in your existing contracts?

Antony Koblish: You were a little blurry there, Caitlin. We’re sitting in a hotel room with a landline, which is now ancient technology, so if you could just repeat that, that would be great.

Caitlin Cronin: Sure. Yes, no worries. It was just on GPO contracting and how you’re ramping in your existing contracts.

Antony Koblish: Thank you. Yes. So we’re about 60% revenue within our GPO partners. Our target for this year is to be around 70%. We think that’s very, very attainable. And if you look at the longest tenured GPO, health trust, and particularly the subset of health trust known as HCA (NYSE:), we may have about a 30% to 35% market share within that organization, within hernia. So I think given time, pressure, addition of clinical data, maturity of our commercial structure and team that we’re slowly proving that we can penetrate into GPOs over the long haul. Obviously, we’ve had the longest start with HCA and health trust, but we should be able to continue that march through the other GPOs. We are in the process of working through contracting for LIQUIFIX to get access to that product and then also other GPOs are going to be coming up for contract late this year. So in addition to focusing mostly this year on implementation and growth within the footprint we have, we also keep our eye on the further processes involved in getting more contracts. We’re very confident that not only will the number of contracts grow, but our penetration will grow as well.

Caitlin Cronin: Awesome. And then just on LIQUIFIX, since the current indication is for polypropylene and polyester mesh, will you be pursuing an indication for use with your ovine based mesh?

Antony Koblish: Absolutely, yes, very, very good reading defined print on that one. Thank you. Yes, so what’s powerful about LIQUIFIX is that it is hyper-aligned with inguinal to start, and it’s very much a product that is going to be used with the vast majority of the inguinal meshes used today, that is to say polypropylene and polyester. So it’s going to give us the ability to interact with surgeons who do not use our products today and it’s going to give us a tremendous entry point and platform to present our new IHR portfolio, our whole hernia portfolio, really. And so I think it’s going to be a very important driver of the hernia franchise for this year. And then as the contracting, et cetera, starts to come into play, as this year goes forward and through next year, I think LIQUIFIX itself will start to become an excellent contributor in the business as well. So there’s a couple things that have to happen that we have our eye on working with AMS, who’ve been a tremendous partner so far in the launch phase, very much participating with us in the rollout here at the national sales meeting. One is expanding indication to things like ventral hernia, and two is expanding indication to our product and biologic products. In Europe, LIQUIFIX has been used for several years. There’s hundreds of thousands of procedures that are done with it. It’s a very good learning curve and tips and pearls for us to tap into. There’s a published paper, one of the surgeons out of the UK, Mr. Wilson, has done hundreds of cases of LIQUIFIX in combination with all biologic products, including our products. So we know that it works. We just have to do the work to drive the expansion of indications and different products. That said, there’s more than enough to work with the LIQUIFIX label that we have now, since most inguinals are repaired with synthetic mesh and it’s a great door opener for us as well.

Caitlin Cronin: Awesome. Thanks so much for taking the questions.

Roberto Cuca: Thanks, Caitlin.

Operator: Thank you. [Operator Instructions] And our next question is going to come from the line of Michael Sarcone with Jefferies. Your line is open. Please go ahead.

Michael Sarcone: Good afternoon and thanks for taking my questions.

Antony Koblish: Thank you.

Michael Sarcone: Just on the sales incentive programs, you talked about how there are synergies, excuse the background noise, when you can get a rep selling more than one product into accounts and I think you said it could be three to four, not one plus one and two. I was wondering if you can give us a little more color on what proportion of the sales force today is kind of selling one product versus two, or just any kind of split for sales force and where that could ultimately go over time?

Antony Koblish: Thanks for the question, Mike. So pretty much all of our sales reps today are selling some of each product. What I’d say is that those who are selling close to balanced selling, what we’re trying to achieve with the incentive program represent probably about a third of our sales force. So if we can move the other two-thirds of the sales force to something closer. We believe that that dynamic of the one plus one equaling three to four will benefit the whole portfolio. So we’re not going to put in place incentives that require them to jump from selling, let’s say 5% PRS or 5% hernia to 50-50 immediately, but we’re putting in a plan that will gradually grow them, incentivize them to grow to much more balanced selling, something that will look more similar to the breakdown between the two products across our portfolio.

Michael Sarcone: Got it. That’s helpful. Thank you. And then just second question from me, just on cash burn, can you talk about how you expect cash to trend through the year?

Antony Koblish: Well, in the same way that with reasonably level OpEx, over the course of the year and increasing revenue, we should be seeing operating income and actually operating loss and net loss decrease directionally over the course of the year. We expect cash burn to be doing the same thing. There is a little bit of seasonality in how our cash is spent with building of inventory and payment of incentive compensation, for example. But directionally, cash burn should be decreasing somewhat similarly to the decrease in operating income or loss.

Michael Sarcone: Thank you.

Antony Koblish: Thanks.

Operator: Thank you. [Operator Instructions] And our next question is going to come from the line of David Turkaly with JMP Securities. Your line is open. Please go ahead.

David Turkaly: Hey, good evening, guys. You mentioned the accounts using both are twice as valuable. I’m just curious, are you able to give us an update on how many of those accounts you have now? And maybe if you have a target for where you think that’s going to go in 2024?

Antony Koblish: Sorry, you were breaking up at the beginning, what kind of accounts were you asking about?

David Turkaly: Essentially how many are using both today? Like you mentioned, they’re twice as valuable. And then where do you think that’s going this year? If you could maybe throw out an estimate of how that could progress.

Antony Koblish: Yes. So probably about 50% of accounts are using both products. They may not be using them in the same proportion as we sell across our portfolio. There are some smaller hospitals that really don’t do one kind of procedure or another, and so those are just never going to convert. But the larger hospitals that typically do both hernia repair and reconstruction, we do have some of those that really sell primarily or buy primarily one product or the other, which means we’re just not getting to the physicians who are doing the other sort of procedure. So to the extent that we can get our reps talking to and pitching to those physicians as well, they just become more efficient. They can do all their selling in one institution rather than having to get in their car and drive across town, which means that they can be more efficient and effective. So the goal is to get as many of those potential hospitals that could sell, buy both kinds of products up and running and buying both. And so at some point it will be closer to 80% or 90% of our accounts are buying fairly evenly across our portfolio.

David Turkaly: Great. And then on LIQUIFIX, I was wondering if you might comment on ASP and margin profile. I think I saw that the applicator can deliver something like 40 anchors or something like that per procedure. So I’m just curious how we should think about that as we look to this year and then beyond. Thank you.

Antony Koblish: Sure. So we haven’t disclosed the price point, the exact price point. It’s going to be similar to tackers and staplers, and the margin will be at or better than depending on the exact ASP that we’re able to achieve the rest of our portfolio. These are smaller dollar items. They’re really used only as single one even though they have 40 deployments, they’re only used a single one per patient and 40 anchors is quite a bit for these sorts of applications.

David Turkaly: Thank you.

Antony Koblish: Thanks, Dave.

Operator: Thank you. [Operator Instructions] And our next question is going to come from the line of Matthew O’Brien with Piper Sandler. Your line is open. Please go ahead.

Unidentified Analyst: Hey, this is Stu [ph] on for Matt. Thanks for squeezing us in here and taking our questions and congrats on the outstanding quarter. On the rep side of things, can you provide any additional color on the way that I think about is two different cohorts, one being the cohort before the sales force disruption and the other being post that disruption? Can you give any color on the productivity of each group? How quickly the newer reps might near the productivity of the more tenured reps? And is double digit productivity gains the right way to think about the group as a whole here in 2024?

Antony Koblish: Yes. So as I said in the prepared remarks, about three quarters of our reps have been with us for more than six months. So those would be reps that were preceding that disruption that occurred in the third quarter. So about a quarter of them are with us for under six months, or just about six months. What we’re seeing is that they are trending towards the same productivity metric that we’ve seen in the past of achieving breakeven, so covering their own expenses within that six months on average. And we expect that with the additional training that we’re giving them, with the greater breadth of our regional managers now, who manage fewer reps individually, that they will be able to at least achieve the sorts of productivity curves that reps have in the past.

Unidentified Analyst: That’s helpful. And then any color on the pipeline of additional GPOs that might be waiting in the wings, might we see another one of those here in 2024 and is anything like that contemplated in the guidance? Thank you.

Antony Koblish:

Vyvanse: We’re working on some of the really tight regional ones like Kaiser and things like that. I don’t have a good feel for when these are going to come. So far we’ve had excellent track record. We haven’t really been rejected anywhere. So I think it’s a matter of time that’s going to be driven off of when the bid process starts, how long it takes them to process and award the contracts, and then start the contracts. It’s generally a long process. So, like I said, this is the year of implementation more than new contracts. But we can keep the new contract machine going, and I expect it to be end of this year or sometime early next year, where you’ll start to see some additions.

Operator: Thank you. And I’m showing no further questions at this time and I’d like to turn the conference back over to Tony Koblish for any further remarks.

Antony Koblish: Yes. Thank you, Michelle and thank you to everybody for joining us and for your continued interest in TELA Bio. We look forward to catching up with you next time and have a great rest of your afternoon.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.